Intracranial Rosai-Dorfman Disease: pathophysiology, diagnosis and treatment
Michał Szymoniuk1, Aleksandra Dryla1, Michalina Pytka2, Piotr Kamieniak3

1Student Scientific Association of Neurosurgery, Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Jacezewskiego 8, 20-090 Lublin, Poland; michmatsz@gmail.com, ORCID ID: 0000-0001-6061-8089 (M.S.), drylaaleksandra@gmail.com, ORCID ID: 0000-0002-3603-4355 (A.D.)

2 Student Scientific Association at the Department of Experimental Hematonoecology, Medical University of Lublin, Chodżki 1, 20-093 Lublin, Poland; michalinapytka@gmail.com, ORCID ID: 0000-0002-4813-9357 (M.P.)

3 Department of Neurosurgery and Pediatric Neurosurgery in Lublin, Medical University of Lublin, Jacezewskiego 8, 20-090 Lublin, Poland; pkamieniak@poczta.onet.pl, ORCID ID: 0000-0003-4125-6582: (P.K.)

Abstract:
Introduction and purpose:
Rosai-Dorfman Disease (RDD), known also as sinus histiocytosis with massive lymphadenopathy (SHML) is a benign histiocytic proliferative syndrome. The etiology and pathogenesis of RDD remains unclear. Central nervous system involvement is a rare event and concerns approximately 7.8% of RDD cases, whereas intracranial lesions constitute almost 90% of CNS-RDD cases. The aim of this literature review was to summarize current knowledge about the diagnosis and treatment of intracranial manifestation of RDD. We also described possible hypotheses regarding the pathophysioloogy of this disorder.

State of knowledge:
Even though Rosai-Dorfman disease was thought to be a reactive process, recent evidence demonstrate the presence of clonality, which means that in this histiocytosis the process that underlies the pathology is neoplastic. Intracranial lesions caused by RDD can be easily misdiagnosed with many diseases such as meningiomas, malignant gliomas or metastatic tumors. The final diagnosis of Rosai-Dorfman disease should be made based on histologic and immunohistochemical examinations. Current therapeutic options for this condition include
surgery, radiotherapy, chemotherapy, corticosteroids and immunotherapy. Surgical treatment often constitutes the first-line treatment for intracranial RDD and is the most beneficial treatment option. However, the implementation of adjuvant therapies is very important to avoid the recurrence of lesions, which appear in approximately 14% of subjects after about 10 years from surgery.

**Conclusion:**

This literature review presents current data about pathophysiology, diagnosis and treatment of intracranial involvement of Rosai-Dorfman disease. Further studies on this topic should focus on exploring etiologic mechanisms underlying on this pathology and comparing available treatment methods.

**Keywords:** Rosai-Dorfman disease; histiocytosis; central nervous system; intracranial Rosai-Dorfman disease

1. Introduction

Rosai-Dorfman Disease (RDD), known also as sinus histiocytosis with massive lymphadenopathy (SHML) is a benign histiocytic proliferative syndrome described by Rosai and Dorfman in 1969 [1]. This non-Langerhans histiocytosis is a rare disorder with a prevalence about 1:200,000 people [2]. Most commonly, RDD occurs during the first or second decade of life and is presented by bilateral painless cervical lymphadenopathy coexisting with fever, elevated erythrocyte sedimentation rate, polyclonal hypergammaglobulinemia, and neutrophilia [3–5]. The etiology and pathogenesis of RDD remains unclear [6]. In 43% of cases, RDD is connected with extranodal involvement and refers to skin, cavum sinuses, orbit, bones and upper respiratory tract [7]. Central nervous system involvement is a rare event and concerns approximately 7.8% of RDD cases [8]. Intracranial lesions constitute almost 90% of CNS-RDD cases, whereas the cases of RDD involving spinal canal are significantly scarcer, but also have been observed [9]. The intracranial RDD lesions often are dural-based and circumscribed, and may mimics meningioma [10]. Rarely can be manifested as intraventricular masses [11].

In this literature review, we summarized current knowledge about the diagnosis and treatment of intracranial RDD. We also described possible hypotheses regarding the pathophysiology of this disorder. The etiology of RDD still remains unknown and may be significant for discovering further treatment options based on targeting specific molecules essential for the pathological process in this condition.

2. Etiology and pathogenesis of RDD

One of the most popular paradigms concerning histiocytoses origin is whether the process is neoplastic or reactive - in LCH (Langerhans cell histiocytosis) it is already known that the neoplastic process is involved in this disease pathogenesis due to certain genes’ activation [12–14]. Even though the histological evaluation shows alterations in cellularity and accumulation of activated, large histiocytes with abundant eosinophilic cytoplasm and atypical nuclei accompanied by inflammatory background or fibrosis [15–18], exact genes were tackled in RDD people, which demonstrates the neoplastic origin of this disease [19–23]. Recent research suggests that RDD onset is correlated with the excessed immune response of the haematolymphoid system to infection, which leads to transferring circulating monocytes into activated macrophages (not dendric cells) - future histiocytes [24]. The cellularity is high with plenty of lymphocytes, enlarged histiocytes and emperipolesis, sometimes accompanied by neutrophils and plasma cells as well [18]. Previously RDD histiocytes were thought to be polyclonal, reactive and non-malignant [25]. Cells express CD14, CD163, CD68 and fascin. They are CD1a- and CD207- and are strongly S100 positive [21,26,27].
Up to 33% of patients express abnormalities in KRAS, NRAS, MAP2K1 and ARAF genes, which are correlated with the neoplastic origin [19–23,28]. Some cases go along with familial heredity, especially in families with a germline mutation in the SLC20A3 gene[29]. RDD appears more frequently in people with immunological dysregulates (autoimmune diseases, lymphomas)[26,30,31]. Another important predictive prognostic marker is OCT2[32].

3. Diagnosis of intracranial RDD

3.1. Radiological features

There is a lack of characteristic, pathognomonic symptoms in radiological imaging of Rosai–Dorfman disease. The most frequently found radiological image presents a single intracranial mass, multiple lesions also have been noted [33,34]. Intracranial masses are homogeneously enhanced, located on the base of the dura mater, external to the brain parenchyma with vasogenic edema [35,36]. Moreover, changes are well-restricted and located on convexities regions, parasagittal, cranial base, sellar and super-sellar areas [37,38].

Intracranial mass on CT without contrast presents as an iso- or hyperdense [39]. Moreover, this image can be linked with the erosion of the neighboring bone[40,41]. On this diagnostic imaging surrounding oedema and homogeneous enhancement appears [33].

Masses on MRI images are mainly isointense on T1-weighted imaging with heterogenous, distinct intensification. On T1-weighted imaging with gadolinium contrast dural tail sign is often present [42]. RDD lesions are iso- or low hyperintense on T2-weighted MRI [10,40,42–46]. The macrophages producing free radicals during phagocytosis might be the reason of presence T2-weighted areas with low intensity [47].

What is more, fluorodeoxyglucose positron emission tomography/computed tomography can be used in diagnosing relapsed intracranial Rosai-Dorfman disease, this was outlined by Deshayes et al. who used this method to diagnose relapsed RDD of the hypothalamus [48].

3.2. Pathological features

Histologic and immunohistochemical examinations are pathologic examinations that can prove a final diagnosis of Rosai-Dorfman disease [49].

Common histological findings contain lymphocytes, plasma cells, foamy macrophages and huge, clear-cut histiocytes with phagocytic vacuoles [50–53]. Histiocytes in Rosai-Dorfman disease are pale and have oval or round vesicular nuclei with clear-cut nuclear membranes and single nucleoli and create patterns with lymphoplasma cells which infiltration is weakened [2]. Histologically, sometimes eosinophils and neutrophils may be present [2]. What is more, in extranodal involvement of RDD fibrosis can be present.

Emperipoliesis is a distinguishing but not a specific feature of RDD, it is only current in 87% of RDD in CNS [54,55]. This histological hallmark consists in the presence and penetrating of an intact cell without cytoplasm another living cell. In Rosai-Dorfman disease mature lymphocytes, erythrocytes and plasma cells are located in histiocytes' phagocytic vacuoles [37,50,56]. Specific immunohistochemical stains are needed because of the lack of identifiable infectious agents related to mixed, dense and chronic inflammatory infiltrate with a significant histiocytic component [50,57]. The presence of histiocytes is confirmed by positive staining for CD68, CD163 and S-100 protein. Moreover, cells are immunoreactive for HAM 56, α1 chymotrypsin, Mac 387, α1 antitrypsin, Ki-1 and lysozyme, but negative for CD1a and EMA [33,58–64].

3.3. Differential diagnosis
Rosai-Dorfman disease might be mistaken with other diseases like meningiomas, malignant gliomas, metastatic tumors, pseudotumors, lymphomas, histiocytosis X, tuberculosis, neurofibromatosis, sarcoidosis and granulomatous diseases [40,65].

Radiographically, RDD can be mistaken with meningioma, both diseases are dura-based and extra-axial lesions [50]. Things, that can help with differentiation are facts that meningioma in angiographic studies shows an absence of hypervascularity and on T2-weighted images of Rosai-Dorfman disease low hyperintense areas are present. In contrast to RDD, meningiomas are usually hypervascular lesions. What is more, on CT images in the case of meningioma hemorrhages or calcifications might be seen [10], common in meningiomas are also hyperostosis and bone erosion in contrast to RDD [42,50]. Magnetic resonance spectroscopy can also be helpful with the differentiation of RDD and meningioma, in the case of RDD choline peak reaches 140 ppm, but the second disease shows an alanine peak on 48 ppm [43].

The presence of CD68 and S-100 indicates histiocytes. Therefore infectious diseases and granulomatous can be excluded [50]. Positive staining for S-100 can exclude Erdheim-Chester disease, but can not eliminate Langerhans cell histiocytosis [66], which is also S-100 positive. Differentiation is possible thanks to CD1a, CD207 and V600E negativity in RDD [25,56,58,61]. Moreover, histiocytes in Langerhans cell histiocytosis show reniform or indented nuclei and Birbeck granules are present [67-71].

4. Treatment of intracranial RDD

Although RDD is considered a benign condition and almost 50% of cases of sporadic RDD demonstrate spontaneous recovery without application of any treatment, remission is not observed in the case of intracranial RDD [6]. Current therapeutic options for this condition include surgery, radiotherapy, chemotherapy, corticosteroids and immunotherapy. However, no unified treatment scheme has been established and therapy should be tailored for the individual patient depending on their clinical presentation [16].

4.1. Surgical resection

Surgical treatment often constitutes the first-line treatment for intracranial RDD. In many of cases, surgery is performed when RDD is misdiagnosed as meningioma based on clinical and radiological findings. Complete surgical resection is the most beneficial treatment option. It improves neurological symptoms and provides tissue for histopathological diagnosis. Gross-total resection (GTR) can be obtained in the majority of intracranial RDD cases and results in long-term satisfactory outcomes [6]. However, RDD lesions may be located in deep brain structures or surrounded by vital neurovascular structures. Thus, GTR is difficult, sometimes even impossible to obtain in these cases [72,73]. Biopsy or subtotal resection performed for such cases significantly increase the risk of RDD recurrence [6]. About 14% of subjects relapse after subtotal resection about after 10 years from surgery [3,64]. Therefore patients after surgical treatment should be clinically and radiologically observed. Regular MRI scans and PET FDG/CT scans can be both useful for this purpose [74]. Moreover, the implementation of adjuvant therapies should be considered[73]. Indeed, the combinatory approach for intracranial RDD demonstrated very satisfactory results [39].

In surgical management of pediatric intracranial RDD staged surgery with 3-5 monthly operation time intervals should be considered due to its better toleration and therapeutic outcomes [75]. Long-term radiological follow-up is necessary and adjuvant treatment may be similarly implemented as in the case of adult intracranial RDD [75].

4.2. Radiotherapy
Radiation therapies are a popular component of adjuvant treatment for intracranial RDD after subtotal resection. Some authors demonstrated the effectiveness of fractionated radiotherapy and stereotactic radiotherapy in relief of the RDD symptoms, especially in the case of recurrent intracranial RDD [16,76] . However, their efficacy remains unclear due to the lack of quality, randomized studies, and variety of patients’ responses observed after these therapies[73,77–79] . A recent systematic review by Tripathi et al, evaluating the use of stereotactic radiosurgery in intracranial histiocytoses, including 2 cases of RDD, emphasized the role of stereotactic radiotherapy in the alternative treatment of intracranial RDD [80] . However, their cohort contained an insufficient number of patients to formulate clear conclusions. Furthermore, there are proposed options, which may increase the efficacy of radiation therapies in RDD including radioenhancers and brachytherapy [81,82] .

4.3. Steroid therapy

Administration of corticosteroids for RDD with intracranial involvement was suggested by some studies [53,77] . Steroid therapy has also demonstrated favorable effects on the reduction of multiple and isolated intracranial masses[83–85] . Moreover, its non-invasiveness constitutes a great advantage among available treatment methods. Thus, steroids can be considered for alternative treatment of RDD not suitable for surgical resection. However, in certain cases recurrence of symptoms and no response to treatment with corticosteroids was demonstrated by some patients [74,86] .

4.4. Chemotherapy

Different chemotherapeutic schemes were used for the treatment of RDD, although the best therapeutic approach for intracranial involvement of RDD has not been established yet [87] . Chemotherapeutic agents investigated in the literature for RDD treatment include methotrexate, anthracyclines, cytarabine, vinca alkaloids, 6-mercaptopurine, etoposide and 2-chlorodeoxyadenosine [6,88–90]. However, their various efficacy raises the question of the use of chemotherapy for RDD treatment.

4.5. Immunotherapy

Recent research gives more and more data about the pathogenesis of RDD. This provides an opportunity to use the immunotherapeutic approach for the treatment of this disease. Some authors reported beneficial effects of the use imatinib (a tyrosine kinase inhibitor) and rituximab (CD20 monoclonal antibody) in therapy of systemic RDD [91,92] . However, their efficacy has not been evaluated in the case of RDD with intracranial involvement. Further studies should investigate the potentially effective targeted agents for treatment of intracranial RDD.

5. Conclusion

The Rosai-Dorfman Disease is a rare syndrome, which in certain cases may involve the central nervous system. Even though Rosai-Dorfman disease was thought to be a reactive process, recent evidence demonstrate the presence of clonality, which means that in this histiocytosis the process that underlies the pathology is neoplastic.

Intracranial lesions caused by RDD can be easily misdiagnosed with many diseases such as meningiomas, malignant gliomas or metastatic tumors. Despite the rarity and benign character of this condition, CNS-involving RDD requires adequate therapy and it should be considered in the differential diagnosis when intracranial mass is discovered. Furthermore, in certain cases, intracranial RDD can manifest with malignant behavior and poor prognosis [57] .

The rarity of intracranial RDD hinders performing high-quality, randomized controlled studies. Thus, the clinical efficacy of available treatment methods is difficult to investigate and
compare. Furthermore, it impedes creating appropriate recommendations for the treatment of this condition. However, based on existing reports, surgical treatment combined with strict, long-term follow-up and adjuvant treatment constitute the best therapeutic approach.

References

1. Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87:63–70.
2. Mahzoni P, Hani M, Zavareh T, Bagheri M, Hani N, Moqtader B. Intracranial ROSAI-DORFMAN Disease. J Res Med Sci. 2012 Mar;17(3):304.
3. Das S, Biswas A, Roy S, Sable MN, Singh D, Jana M, Sharma MC, Julka PK. Recurrent intracranial Rosai-Dorfman disease: Management of a challenging case. Vol. 12, Asian journal of neurosurgery. 2017. p. 537–40.
4. Cheng X, Cheng JL, Gao AK. A Study on Clinical Characteristics and Magnetic Resonance Imaging Manifestations on Systemic Rosai-Dorfman Disease. Chin Med J (Engl). 2018 Feb 20;131(4):440–7.
5. Bueno HF, Agarwalla PK, Chundury A, Baisre de Leon A, Mirani N, Nimchinsky EA. Differentiation of intracranial Rosai-Dorfman histiocytosis from meningioma using MR perfusion. Vol. 10, Clinical case reports. 2022. p. e05737.
6. Zhou C, Ren H, Hong L, Zhang J, Wang H. Clinicopathological characteristics of multiple intracranial Rosai-Dorfman disease with increased IgG4-positive plasma cells: a report of two cases. Vol. 59, Folia neuropathologica. Poland; 2021. p. 409–18.
7. Xia L, Zhang L, Xiang Y, Liu L, Jing Z. Intracranial Rosai-Dorfman disease mimicking isolated meningioma: a case report and review of the literature. Vol. 14, International journal of clinical and experimental pathology. 2021. p. 827–30.
8. Elshikh M, Schellingerhout D, Rayan J, Taher A, Elsayes AK, Mujtaba B, Garg N. Disease Characteristics, Radiologic Patterns, Comorbid Diseases, and Ethnic Differences in 32 Patients With Rosai-Dorfman Disease. J Comput Assist Tomogr. 2020 May 1;44(3):450–61.
9. Qin G, Ye J, Lan S, Liang Y, Xu P, Tang X, Guo W. Rosai-Dorfman disease with spinal and multiple intracranial involvement: a case report and literature review. Br J Neurosurg. 2019;1–5.
10. Zhu H, Qiu LH, Dou YF, Wu JS, Zhong P, Jiang CC, Xu R, Wang XQ. Imaging characteristics of Rosai-Dorfman disease in the central nervous system. Eur J Radiol. 2012;81(6):1265–72.
11. Patwardhan PP, Goel NA. Isolated Intraventricular Rosai-Dorfman Disease. Vol. 13, Asian journal of neurosurgery. 2018. p. 1285–7.
12. Zelger B. Langerhans cell histiocytosis: a reactive or neoplastic disorder? Med Pediatr Oncol. 2001;37(6):543–4.

13. Yohe SL, Chenault CB, Torlakovic EE, Asplund SL, McKenna RW. Langerhans cell histiocytosis in acute leukemias of ambiguous or myeloid lineage in adult patients: support for a possible clonal relationship. Mod Pathol. 2014;27(5):651–6.

14. Gonzalez CL, Jaffe ES. The histiocytoses: clinical presentation and differential diagnosis. Oncology (Williston Park). 1990 Nov 1;4(11):47–60; discussion 60, 62.

15. Rajyalakshmi R, Akhtar M, Swathi Y, Chakravarthi R, Reddy JB, Priscilla MB. Cytological Diagnosis of Rosai–Dorfman Disease: A Study of Twelve Cases with Emphasis on Diagnostic Challenges. J Cytol. 2020 Jan 1;37(1):46.

16. Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, Durham BH, Braier J, Charlotte F, Donadieu J, Cohen-Aubart F, Rodriguez-Galindo C, Allen C, Whitlock JA, Weitzman S, McClain KL, Haroche J, Diamond EL. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018 Jun 28;131(26):2877–90.

17. Goyal G, Ravindran A, Young JR, Shah M V., Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020 Jan 31;105(2):348–57.

18. Alruwaii ZI, Zhang Y, Larman T, Miller JA, Montgomery EA. Rosai-Dorfman Disease of the Digestive System-Beware Vasculopathy: A Clinicopathologic Analysis. Am J Surg Pathol. 2019 Dec 1;43(12):1644–52.

19. Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A. Rosai–Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation. Head Neck Pathol. 2016 Sep 1;10(3):394.

20. Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SCW, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzen C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Heritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov. 2016 Feb 1;6(2):154–65.

21. Nasany RA, Reiner AS, Francis JH, Abla O, Panageas KS, Diamond EL. Rosai-Dorfman-Destombes disease of the nervous system: a systematic literature review. Orphanet J Rare Dis. 2022 Dec 1;17(1).
22. Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. 2020 Nov 1;73(11):697–705.

23. Garces S, Medeiros LJ, Patel KP, Li S, Pina-Oviedo S, Li J, Garces JC, Khoury JD, Yin CC. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017 Oct 1;30(10):1367–77.

24. Middel P, Hemmerlein B, Fayyazi A, Kaboth U, Radzun HJ. Sinus histiocytosis with massive lymphadenopathy: evidence for its relationship to macrophages and for a cytokine-related disorder. Histopathology. 1999;35(6):525–33.

25. Paulli M, Bergamaschi G, Tonon L, Viglio A, Rosso R, Facchetti F, Geerts ML, Magrini U, Cazzola M. Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Br J Haematol. 1995;91(2):415–8.

26. Vaiselbuh SR, Bryceson YT, Allen CE, Whitlock JA, Abla O. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014;61(7):1329–35.

27. Wenig BM, Abbondanzo SL, Childers EL, Kapadia SB, Heffner DR. Extranodal sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) of the head and neck. Hum Pathol. 1993;24(5):483–92.

28. Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX, Pastore A, Yoshiimi A, Mandelker D, Ceyhan-Birsoy O, Ulaner GA, Walsh M, Yabe M, Petrova-Drus K, Arcila ME, Ladanyi M, Solit DB, Berger MF, Hyman DM, Lacouture ME, Erickson C, Saganty R, Ki M, Dunkel IJ, Santa-Maria López V, Mora J, Haroche J, Emile JF, Dechaux O, Geissmann F, Savvides SN, Drilon A, Diamond EL, Abdel-Wahab O. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med. 2019 Dec 1;25(12):1839–42.

29. Morgan N V., Morris MR, Cangul H, Gleeson D, Straitman-Iwanowska A, Davies N, Keenan S, Pasha S, Rahman F, Gentle D, Vreewijk MPG, Devilee P, Knowles MA, Ceylaner S, Trembath RC, Dalence C, Kismet E, Lu VK, Rossbach HC, Gissen P, Tannahill D, Maher ER. Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet. 2010 Feb;6(2).

30. Lu D, Estalilla OC, Manning JT, Jeffrey Medeiros L. Sinus Histiocytosis with Massive Lymphadenopathy and Malignant Lymphoma Involving the Same Lymph Node: A Report of Four Cases and Review of the Literature. Mod Pathol 2000 134. 2000 Apr 1;13(4):414–9.

31. Xie Y, Pittaluga S, Price S, Raffeld M, Hahn J, Jaffe ES, Rao VK, Maric I. Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation. Haematologica. 2017;102(2):364–72.
32. Ravindran A, Goyal G, Go RS, Rech KL. Rosai-Dorfman Disease Displays a Unique Monocyte-Macrophage Phenotype Characterized by Expression of OCT2. Am J Surg Pathol. 2021 Jan 1;45(1):35–44.

33. Maratos EC, Bridges LR, MacKinnon AD, Madigan JB, Atra A, Martin AJ. Isolated intracranial Rosai-Dorfman disease in a child, a case report and review of the literature. Childs Nerv Syst. 2014;30(9):1595–600.

34. Cao XY, Luan SH, Bao WM, Shen C, Yang BJ. Solitary intracranial Rosai-Dorfman disease: Case report and literature review. J Int Med Res. 2011 Oct 1;39(5):2045–50.

35. Toh CH, Chen YL, Wong HF, Wei KC, Ng SH, Wan YL. Rosai-Dorfman disease with dural sinus invasion. Report of two cases. J Neurosurg. 2005 Mar;102(3):550–4.

36. Varan A, Şen H, Akalan N, Oğuz KK, Sağlam A, Akyüz C. Pontine Rosai-Dorfman disease in a child. Child’s Nerv Syst. 2015 Jun 29;31(6):971–5.

37. Camp SJ, Roncaroli F, Apostolopoulos V, Weatherall M, Lim S, Nandi D. Intracerebral multifocal Rosai–Dorfman disease. J Clin Neurosci. 2012 Sep 1;19(9):1308–10.

38. Imada H, Sakatani T, Sawada M, Matsuura T, Fukushima N, Nakano I. A lethal intracranial Rosai-Dorfman disease of the brainstem diagnosed at autopsy. Pathol Int. 2015 Oct 1;65(10):549–53.

39. Wang C, Kuang P, Xu F, Hu L. Intracranial Rosai-Dorfman disease with the petroclival and parasellar involvement mimicking multiple meningiomas: A case report and review of literature. Medicine (Baltimore). 2019 May 1;98(18).

40. Lungren MP, Petrella JR, Cummings TJ, Grant GA. Isolated Intracranial Rosai-Dorfman Disease in a Child. AJNR Am J Neuroradiol. 2009 Nov;30(10):E148.

41. Gupta K, Bagdi N, Sunitha P, Ghosal N. Isolated intracranial Rosai-Dorfman disease mimicking meningioma in a child: a case report and review of the literature. Br J Radiol. 2011 Jul;84(1003):e138.

42. Raslan OA, Schellinghout D, Fuller GN, Ketonen LM. Rosai-Dorfman disease in neuroradiology: imaging findings in a series of 10 patients. AJR Am J Roentgenol. 2011 Feb;196(2).

43. Cheng X, Cheng JL, Gao AK. A Study on Clinical Characteristics and Magnetic Resonance Imaging Manifestations on Systemic Rosai-Dorfman Disease. Chin Med J (Engl). 2018 Feb;131(4):440–7.

44. Griffiths SJ, Tang W, Parameswaran R, Kelsey A, West CGH. Isolated intracranial Rosai-Dorfman disease mimicking meningioma in a child. https://doi.org/10.1080/02688690410001732788. 2009 Jun;18(3):293–7.
45. Theeler BJ, Keylock JB, Yoest SM. Teaching NeuroImage: Isolated intracranial Rosai-Dorfman disease mimicking a meningioma. Neurology. 2008 Mar;70(13 PART 1).
46. Udono H, Fukuyama K, Okamoto H, Tabuchi K. Rosai-Dorfman disease presenting multiple intracranial lesions with unique findings on magnetic resonance imaging. Case report. J Neurosurg. 1999;91(2):335–9.
47. Alimli AG, Oztunali C, Boyunaga OL, Pamukcuoglu S, Okur A, Borcek AO. MRI and CT findings of isolated intracranial Rosai–Dorfman disease in a child. Neuroradiol J. 2016 Apr 1;29(2):146.
48. Deshayes E, Le Berre JP, Jouanneau E, Vasiljevic A, Raverot G, Seve P. 18F-FDG PET/CT findings in a patient with isolated intracranial Rosai-Dorfman disease. Clin Nucl Med. 2013;38(1).
49. Tian Y, Wang J, Ge J zhao, Ma Z, Ge M. Intracranial Rosai-Dorfman disease mimicking multiple menigiomas in a child: a case report and review of the literature. Childs Nerv Syst. 2015 Feb 1;31(2):317–23.
50. Krueger EM, Brown HG, Schaible K. Multiple Intracranial Rosai-Dorfman Disease: A Case Report. Cureus. 2019 Jul 31;11(7).
51. Hinduja A, Aguilar LG, Steineke T, Nochlin D, Landolfi JC. Rosai-Dorfman disease manifesting as intracranial and intraorbital lesion. J Neurooncol. 2009;92(1):117–20.
52. Sundaram C, Uppin SG, Prasad BCM, Sahu BP, Devi MU, Prasad VSSV, Purohit AK. Isolated Rosai Dorfman disease of the central nervous system presenting as dural-based and intraparenchymal lesions. Clin Neuropathol. 2005 May 1;24(3):112–7.
53. Johnson MD, Powell SZ, Boyer PJ, Weil RJ, Moots PL. Dural lesions mimicking menigiomas. Hum Pathol. 2002 Dec 1;33(12):1211–26.
54. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7:19–73.
55. Foucar E, Rosai J, Brynes RK. The neurologic manifestations of sinus histiocytosis with massive lymphadenopathy. Neurology. 1982;32(4):365–71.
56. Piris MA, Aguirregoicoa E, Montes-Moreno S, Celeiro-Muñoz C. Castleman Disease and Rosai-Dorfman Disease. Semin Diagn Pathol. 2018 Jan 1;35(1):44–53.
57. Riccio L, Donofrio CA, Serio G, Melatini A. Malignant behaviour of primary intracranial Rosai Dorfman disease: A rare presentation of a benign disease. Neurochirurgie. 2021 Apr 1;67(2):205–9.
58. Paulli M, Rosso R, Kindl S, Boveri E, Marocolo D, Chioda C, Agostini C, Magrini U, Facchetti F. Immunophenotypic characterization of the cell infiltrate in five cases of sinus
histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Hum Pathol. 1992;23(6):647–54.

59. Mirra SS, Tindall SC, Check IJ, Brynes RK, Moore WW. Inflammatory meningeal masses of unexplained origin. An ultrastructural and immunological study. J Neuropathol Exp Neurol. 1983;42(4):453–68.

60. Andriko JAW, Morrison A, Colegial CH, Davis BJ, Jones R V. Rosai-Dorfman disease isolated to the central nervous system: a report of 11 cases. Mod Pathol. 2001;14(3):172–8.

61. Eisen R, Buckley P, Rosai J. Immunophenotypic characterization of sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease). Semin Diagn Pathol. 1990;7:74 – 82.

62. Walid MS, Grigorian AA. Ethmo-spheno-intracranial Rosai-Dorfman disease. Indian J Cancer. 2010 Jan 1;47(1):80.

63. Raslan O, Ketonen LM, Fuller GN, Schellingerhout D. Intracranial Rosai-Dorfman disease with relapsing spinal lesions. J Clin Oncol. 2008;26(18):3087–9.

64. Adeleye AO, Amir G, Fraifeld S, Shoshan Y, Umansky F, Spektor S. Diagnosis and management of Rosai-Dorfman disease involving the central nervous system. Neurol Res. 2010 Jul 1;32(6):572–8.

65. Bing F, Brion JP, Grand S, Pasquier B, Lebas JF. Tumor arising in the periventricular region. Neuropathology. 2009 Feb;29(1):101–3.

66. Asai A, Matsutani M, Kohno T, Fujimaki T, Tanaka H, Kawaguchi K, Koike M, Takakura K. Leptomeningeal and orbital benign lymphphagocytic histiocytosis: Case report. J Neurosurg. 1988 Oct 1;69(4):610–2.

67. Wu M, Anderson AE, Kahn LB. A report of intracranial Rosai-Dorfman disease with literature review. Ann Diagn Pathol. 2001 Apr 1;5(2):96–102.

68. Schmitt F. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): cytomorphologic analysis on fine-needle aspirates. Diagn Cytopathol. 1992;8:596 – 599.

69. Trautman B, Stanley M, Goding G. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): diagnosis by fine-needle aspiration. Diagn Cytopathol. 1991;7:513 – 516.

70. Sanchez R, Sibley RK, Rosai J, Dorfman RF. The electron microscopic features of sinus histiocytosis with massive lymphadenopathy: a study of 11 cases. Ultrastruct Pathol. 1981;2(2):101–19.

71. Huang HY, Huang CC, Lui CC, Chen HJ, Chen WJ. Isolated intracranial Rosai—Dorfman disease: Case report and literature review. Pathol Int. 1998 May 1;48(5):396–402.
72. Boissaud-Cooke MA, Bhatt K, Hilton DA, Muquit S. Isolated Intracranial Rosai-Dorfman Disease: Case Report and Review of the Literature. Vol. 137, World neurosurgery. United States; 2020. p. 239–42.

73. Sandoval-Sus JD, Sandoval-Leon AC, Chapman JR, Velazquez-Vega J, Borja MJ, Rosenberg S, Lossos A, Lossos IS. Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature. Medicine (Baltimore). 2014;93(3):165–75.

74. Zhu Q, Liang Y, Fan Z, Liu Y, Zhou C, Zhang H, Li T, Zhou Y, Yang J, Wang L. Management of central nervous system Rosai-Dorfman disease: A single center treatment experience. J Clin Neurosci. 2022 May;99:275–81.

75. Zhang J, Li D, Cheng R, Zhang N, Ni X, Ge M. Staging surgery for intraventricular bilateral giant Rosai-Dorfman disease in children. Vol. 6, Pediatric investigation. 2022. p. 50–4.

76. Joshi SS, Joshi S, Muzumdar G, Turel KE, Shah RM, Ammbulkar I, Hussain MM, Choudhari KA. Cranio-spinal Rosai Dorfman disease: case series and literature review. Br J Neurosurg. 2019 Apr;33(2):176–83.

77. Hadjipanayis CG, Bejjani G, Wiley C, Hasegawa T, Maddock M, Kondziolka D. Intracranial Rosai-Dorfman disease treated with microsurgical resection and stereotactic radiosurgery. Case report. J Neurosurg. 2003 Jan 1;98(1):165–8.

78. Kidd DP, Revesz T, Miller NR. Rosai-Dorfman disease presenting with widespread intracranial and spinal cord involvement. Neurology. 2006;67(9):1551–5.

79. Petzold A, Thom M, Powell M, Plant GT. Relapsing intracranial Rosai-Dorfman disease. J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):538.

80. Tripathi M, Maskara P, Deora H, Bansal D, Mohindra S, Tripathi S, Kaur R, Sheehan JP, Rana R, Kumar N. Role of Stereotactic Radiosurgery in Intracranial Histiocytosis: a Systematic Review of Literature of an Emerging Modality for Localized Disease. World Neurosurg. 2021 Jun;150:64–70.

81. Ganau M, Foroni RI, Gerosa M, Ricciardi GK, Longhi M, Nicolato A. Radiosurgical options in neuro-oncology: A review on current tenets and future opportunities. Part II: Adjuvant radiobiological tools. Tumori. 2015 Jan 1;101(1):57–63.

82. Tatit RT, Raffa PEAZ, de Almeida Motta GC, Bocchi AA, Guimaraes JL, Franceschini PR, de Aguiar PHP. Rosai-Dorfman disease mimicking images of meningiomas: Two case reports and literature review. Vol. 12, Surgical neurology international. 2021. p. 292.

83. Zhang JT, Tian HJ, Lang SY, Wang XQ. Primary intracerebral Rosai-Dorfman disease. J Clin Neurosci. 2010 Oct;17(10):1286–8.

84. McPherson CM, Brown J, Kim AW, DeMonte F. Regression of intracranial rosai-dorfman disease following corticosteroid therapy. Case report. J Neurosurg. 2006 May;104(5):840–4.
85. Siu RCH, Tan IL, Davidson AS, Robertson A, Fraser CL. Clinical Reasoning: Compressive optic neuropathy secondary to intracranial Rosai-Dorfman disease. Neurology. 2015 Sep 22;85(12):e89–92.

86. Pagel JM, Lionberger J, Gopal AK, Sabath DE, Loeb K. Therapeutic use of Rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) [2]. Am J Hematol. 2007 Dec;82(12):1121–2.

87. Jamali E, Sharifi G, Ghafouri-Fard S, Bidari Zerehpoosh F, Yazdanpanahi M, Taheri M. Intracranial Rosai Dorfman Disease Presented With Multiple Huge Intraventricular Masses: A Case Report. Vol. 9, Frontiers in surgery. 2022. p. 766840.

88. Wang W, Sun J, Zhang W, Zhou D. Successful treatment of intracranial Rosai-Dorfman disease with cytarabine and dexamethasone: case report and review of literature. Vol. 99, Annals of Hematology. Germany; 2020. p. 1157–9.

89. Tasso M, Esquembre C, Blanco E, Moscardó C, Niveiro M, Payá A. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2006 Oct 15;47(5):612–5.

90. Rivera D, Pérez-Castillo M, Fernández B, Stoeter P. Long-term follow-up in two cases of intracranial Rosai–Dorfman Disease complicated by incomplete resection and recurrence. Surg Neurol Int. 2014;5(Supplement).

91. Singh A, Simons Y, Biren-Fetz J, Mohapatra G, Ni H, Gaitonde S, Khan I. Extended treatment response to imatinib in Rosai-Dorfman disease. Eur J Haematol. 2021 Jun 1;106(6):868–70.

92. Alqanatish JT, Houghton K, Bond M, Senger C, Tucker LB. Rituximab treatment in a child with rosai-dorfman disease and systemic lupus erythematosus. J Rheumatol. 2010 Aug;37(8):1783–4.